Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:10:34 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ATAI - ATAIBECKLEY INC - https://ir.atai.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATAI - Q30.03.59·3.925.03.77+0.3610.64,549.515,91512,1863.44  3.80  3.446.725  1.1519:45:27Jan 1615 min RT 2¢

Recent Trades - Last 10 of 12186
Time ETExPriceChangeVolume
19:45:27Q3.750.3439
19:42:04Q3.750.342
19:18:23Q3.700.29200
19:07:02Q3.74770.337730
19:06:44Q3.700.29100
17:53:36Q3.700.2960
17:48:05Q3.68220.2722200
17:24:17Q3.800.395
17:19:21Q3.800.3951
16:51:31Q3.790.38600

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-16 07:00U:ATAINews ReleaseAtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
2026-01-08 07:00U:ATAINews ReleaseAtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
2025-12-30 19:13U:ATAINews ReleaseAtaiBeckley Completes Redomiciliation to the United States
2025-12-23 07:00U:ATAINews ReleaseAtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
2025-12-11 07:00U:ATAINews ReleaseAtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
2025-11-19 19:32U:ATAINews ReleaseEnhanced Fortifies Executive Leadership Team & Board of Directors
2025-11-13 09:00U:ATAINews ReleaseAtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
2025-11-12 07:00U:ATAINews ReleaseAtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
2025-11-10 07:00U:ATAINews ReleaseAtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
2025-11-05 07:00U:ATAINews Releaseatai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
2025-10-20 17:30U:ATAINews Releaseatai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
2025-10-16 22:32U:ATAINews Releaseatai Life Sciences Announces Pricing of Public Offering of Common Shares
2025-10-16 16:13U:ATAINews Releaseatai Life Sciences Announces Proposed Public Offering of Common Shares
2025-10-16 16:11U:ATAINews Releaseatai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
2025-09-23 07:00U:ATAINews Releaseatai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
2025-09-18 08:00U:ATAINews Releaseatai Life Sciences Awarded Grant from the National Institutes of Health
2025-08-28 16:05U:ATAINews Releaseatai Life Sciences to Participate in September Investor Conferences
2025-08-14 07:00U:ATAINews Releaseatai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
2025-07-25 16:05U:ATAINews ReleaseRecognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
2025-07-01 09:50U:ATAINews ReleaseGlobal Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032